A team from Peking Union Medical College Hospital in Beijing published a review article in the World Journal of Pediatrics on July 23 that introduces a new clinical framework for mapping pediatric Behçet’s spectrum disorders. The framework aims to address challenges in diagnosing Behçet's disease and related conditions in children, where symptoms are often partial or atypical and can overlap with other monogenic autoinflammatory disorders.
The researchers propose a tiered classification system: 'core Behçet's spectrum disorders (BSD)' for monogenic diseases directly affecting key inflammatory pathways, and 'peripheral BSD' for conditions with partial clinical overlap or indirect mechanistic connections. According to the authors, "We're not saying these are all the same disease—they're not. But they converge on the same inflammatory circuits. If a child shows up with recurrent mouth ulcers, fever, and gut inflammation that doesn't quite fit Behçet's criteria, the BSD framework gives us a roadmap for what to test for and why." They said the approach is particularly valuable in early-onset or atypical cases where genetic testing can distinguish between similar-looking but biologically distinct conditions.
The systematic review details how core BSD includes monogenic diseases such as HA20 (TNFAIP3 mutations), RELA haploinsufficiency, NFKB1 haploinsufficiency, and ELF4 deficiency—all of which disrupt NF-κB or JAK-STAT signaling pathways central to Behçet’s pathology. Peripheral BSD encompasses polygenic or multifactorial entities like recurrent aphthous stomatitis (RAS), PFAPA syndrome, DADA2, and trisomy 8-associated disease that share some features but lack defining genetic drivers.
The authors emphasize that this biology-driven classification does not replace existing diagnostic criteria, but provides clinicians with a mechanism-oriented lens to prioritize genetic screening in children presenting with complex symptoms. This approach could help reduce misdiagnosis and inappropriate treatment by clarifying diagnostic boundaries between true spectrum members and phenotypic mimics such as LIG4 deficiency or IKBKG (NEMO) mutations.
Clinically, the new BSD framework is designed to enable earlier recognition of relevant phenotypes and guide targeted therapies—such as IL-1, TNF, or JAK inhibitors—for specific patient subsets. It also seeks to avoid unnecessary investigations by excluding non-spectrum mimics more efficiently. Scientifically, it offers an integrated view of disparate inflammatory disorders under shared pathogenic mechanisms.
